There are just two years remaining on the clock for developing nations to achieve the Millennium Development Goals, including Goal Six, targeting the global fight against AIDS, TB and malaria.
You are here
The people involved in the Global Fund, and in global health generally, “are at an historic moment when the confluence of scientific advancement, epidemiological intelligence and experience from more than a decade of implementation come together to offer the opportunity to end three plagues as public health threats.”
The Global Fund Board will not approve funding for Phase 2 of two Round 8 malaria grants to the Republic of Congo.
The Global Fund Board has approved up to $40.5 million for four interim applicant countries: Chad, Papua New Guinea (PNG), Kenya and Mozambique. The Board decisions were based on recommendations from the Grant Approvals Committee (GAC). This brings to five the number of interim applicant countries that have received funding.
Procurement costs for HIV, TB and malaria commodities have either come down or remained stable over the past seven years, according to an analysis conducted by Frank Wafula, Ambrose Agweyu and Kate Macintyre at Aidspan. The findings of the analysis are described in a working paper published on April 29, 2013 on the Aidspan website.
The Government of Azerbaijan has stepped up its funding for HIV, TB and malaria as a result of the departure or anticipated departure of several donors. The government has started funding opiate substitution therapy (OST) and has begun procuring antiretroviral drugs (ARVs), sufficient to meet 20% of the national need.
The Global Fund Board has approved Phase 2 funding for a Round 2 malaria rolling continuation channel grant in Namibia. The principal recipient (PR) for this grant is the National Malaria Control Programme (NMCP) in the Ministry of Health and Social Services. In approving the Phase 2 funding, the Board was acting on recommendations from the Grants Renewal Panel in the Secretariat.
Global Fund Executive Director Mark Dybul says that the disease split for the funding allocated to early and interim applicants in the transition phase of the new funding model (NFM) should not be viewed in isolation, but rather in the context of all funding for 2013–2014.
The Affordable Medicine Facility–malaria (AMFm) endangers public health, according to Oxfam. There are alternative approaches that can deliver better health outcomes for poor people, the agency said in a report released on 24 October 2012.